Palatin Technologies PTN
NASDAQ PTN
$10.32 -0.13 (-1.23%)
As of: Aug 21, 2026 · 12:53 PM EDT

Palatin Technologies (PTN) Total Non-Current Liabilities (2015 - 2024)

Palatin Technologies' (PTN) quarterly Total Non-Current Liabilities came in at $10.0 million in Q3 2024, down 29.17% YoY from $14.1 million in Q4 2023, and down 7.92% on a QoQ basis from $10.9 million in Q2 2024.

Palatin Technologies (PTN) Total Non-Current Liabilities (2015 - 2024) Analysis & Trends

Palatin Technologies (PTN) has 10 years of Total Non-Current Liabilities data on file, last reported at $10.0 million in Q3 2024.

  • Quarterly Total Non-Current Liabilities fell 29.17% year-over-year to $10.0 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $10.0 million (down 29.17% YoY) and the FY2024 annual result came in at $10.9 million, down 39.04% from the prior year.
  • Total Non-Current Liabilities slipped to $10.0 million in Q3 2024, from $10.9 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $23.4 million in Q4 2023 to a low of $3.4 million in Q1 2020.
  • A 5-year average of $12.3 million and a median of $11.9 million in 2022 frame the typical range for Total Non-Current Liabilities.
  • Annual changes were most pronounced in 2020 — Total Non-Current Liabilities surged 489.5% — and 2024, when it tumbled 39.04%.
  • Tracing PTN's Total Non-Current Liabilities over 5 years: stood at $8.1 million in 2020, then surged by 82.41% to $14.8 million in 2021, then fell by 19.51% to $11.9 million in 2022, then jumped by 96.71% to $23.4 million in 2023, then slumped by 57.31% to $10.0 million in 2024.
  • The last three Total Non-Current Liabilities figures came in at $10.0 million (Q3 2024), $10.9 million (Q2 2024), and $8.8 million (Q1 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Vertex Pharmaceuticals 139.03 Bn 131.18 Bn 2.84 Bn 5.92 Bn
2 Regeneron Pharmaceuticals 85.64 Bn 77.64 Bn 3.93 Bn 7.74 Bn
3 Argenx Se 64.93 Bn 59.75 Bn 1.37 Bn 40.00 Mn
4 Moderna 57.93 Bn 52.80 Bn 52.00 Mn 3.92 Bn
5 BeOne Medicines 41.95 Bn 36.86 Bn 1.53 Bn 1.88 Bn
6 Alnylam Pharmaceuticals 31.51 Bn 28.20 Bn 992.69 Mn 4.20 Bn
7 BioNTech SE 28.00 Bn 9.60 Bn 668.28 Mn 724.15 Mn
8 Insmed 27.42 Bn 26.26 Bn 358.27 Mn 1.17 Bn
9 Royalty Pharma 27.29 Bn 26.45 Bn - 9.32 Bn
10 Palatin Technologies 40.37 Mn 40.37 Mn - -

Historic Data

Download Data
DateValue
Sep 30, 2024 9.99 Mn
Jun 30, 2024 10.85 Mn
Mar 31, 2024 8.80 Mn
Dec 31, 2023 23.41 Mn
Sep 30, 2023 14.11 Mn
Jun 30, 2023 17.81 Mn
Mar 31, 2023 12.24 Mn
Dec 31, 2022 11.90 Mn
Sep 30, 2022 16.45 Mn
Jun 30, 2022 16.94 Mn
Mar 31, 2022 12.74 Mn
Dec 31, 2021 14.78 Mn
Sep 30, 2021 10.60 Mn
Jun 30, 2021 11.41 Mn
Mar 31, 2021 11.02 Mn
Dec 31, 2020 8.11 Mn
Sep 30, 2020 13.56 Mn
Jun 30, 2020 4.88 Mn
Mar 31, 2020 3.36 Mn
Dec 31, 2019 1.37 Mn